Overall (N =1309) | By smoking status | |||
---|---|---|---|---|
Never-smokers (N=836) | Former smokers (N = 206) | Current smokers (N = 267) | ||
HPV status | mPR†‡ | mPR‡§ | mPR‡§ | mPR‡§ |
Any HPV | ||||
Q1 | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
Q2 | 1.01 (0.88–1.16) | 1.16 (0.97–1.39) | 0.72 (0.39–1.34) | 0.81 (0.62–1.06) |
Q3 | 1.00 (0.88–1.15) | 1.11 (0.92–1.33) | 0.83 (0.48–1.43) | 0.80 (0.61–1.06) |
Q4 | 1.13 (1.00–1.27) | 1.22 (1.03–1.44) | 0.90 (0.57–1.42) | 0.99 (0.79–1.23) |
Q1–Q3 | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
Q4 | 1.12 (1.03–1.23) | 1.12 (0.99–1.26) | 1.03 (0.72–1.48) | 1.14 (0.95–1.37) |
Oncogenic | ||||
Q1 | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
Q2 | 1.09 (0.85–1.42) | 1.38 (0.99–1.90) | 0.54 (0.17–1.68) | 0.77 (0.48–1.24) |
Q3 | 1.11 (0.87–1.43) | 1.25 (0.90–1.75) | 1.01 (0.46–2.25) | 0.75 (0.46–1.23) |
Q4 | 1.35 (1.08–1.68) | 1.48 (1.09–2.02) | 1.10 (0.54–2.23) | 1.04 (0.71–1.53) |
Q1–Q3 | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
Q4 | 1.26 (1.07–1.47) | 1.23 (0.99–1.52) | 1.20 (0.70–2.04) | 1.26 (0.94–1.70) |
Non-oncogenic | ||||
Q1 | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
Q2 | 0.78 (0.50–1.22) | 1.01 (0.55–1.85) | 0.69 (0.25–1.89) | 0.58 (0.24–1.43) |
Q3 | 0.98 (0.65–1.48) | 1.31 (0.75–2.28) | 0.66 (0.23–1.85) | 0.73 (0.31–1.69) |
Q4 | 1.20 (0.83–1.74) | 1.56 (0.91–2.67) | 0.89 (0.38–2.06) | 0.90 (0.44–1.84) |
Q1–Q3 | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
Q4 | 1.30 (0.97–1.73) | 1.39 (0.93–2.08) | 1.15 (0.60–2.20) | 1.18 (0.67–2.07) |
HPV 6, 11, 16 or 18¶ | ||||
Q1 | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
Q2 | 1.01 (0.63–1.61) | 1.41 (0.77–2.55) | 0.26 (0.03–2.17) | 0.69 (0.26–1.80) |
Q3 | 1.15 (0.73–1.79) | 1.33 (0.73–2.41) | 0.96 (0.31–2.92) | 0.65 (0.25–1.74) |
Q4 | 1.47 (0.98–2.23) | 1.73 (0.99–3.03) | 0.75 (0.25–2.25) | 1.14 (0.52–2.50) |
Q1–Q3 | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
Q4 | 1.39 (1.04–1.88) | 1.40 (0.93–2.09) | 0.86 (0.38–1.92) | 1.50 (0.84–2.67) |
Bold font indicates a statistically significant HR.
*Alcohol intake was categorised by the quartile intake values among HPV-negative men.
†Adjusted for age, race, smoking status, ethnicity, circumcision and total number of female partners in the last 3 months.
‡We did not adjust for sex with male partners since over 94% of the men in this analysis reported having zero male partners and there was no difference (p=0.739) across quartiles of alcohol intake as noted in Table 1.
§Adjusted for age, race, ethnicity, circumcision and total number of female partners in the last 3 months.
¶HPV 6, 11, 16 or 18 are the quadrivalent vaccine HPV types.
mPR, multivariable prevalence ratio; Qn, quartile.